Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study. Kallieri M, Papaioannou AI, Zervas E, Fouka E, et al. Clin Exp Allergy 2023 Dec 12. doi: 10.1111/cea.14436.

Read + Share

Amedeo Smart

Independent Medical Education

Kallieri M, Papaioannou AI, Zervas E, Fouka E, et al. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study. Clin Exp Allergy 2023 Dec 12. doi: 10.1111/cea.14436.
PMID: 38084474